BRIEF-FDA grants priority review to Merck's application to expand use of Keytruda in hodgkin lymphoma

* FDA grants priority review to supplemental biologics license application (SBLA) for Merck's Keytruda (Pembrolizumab) in relapsed or refractory classical Hodgkin Lymphoma Source text for Eikon: Further company coverage: